Business Description
OncoZenge AB
ISIN : SE0015504097
Share Class Description:
OSTO:ONCOZ: Ordinary SharesTotal Employee Number:
1Compare
Compare
Traded in other countries / regions
ONCOZ.Sweden8LY.Germany IPO Date
2021-02-12Description
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 0.77 | |||||
Debt-to-EBITDA | -0.3 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -6.45 | |||||
Beneish M-Score | -1.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 9.3 | |||||
3-Year EPS without NRI Growth Rate | 18.4 | |||||
3-Year FCF Growth Rate | 17 | |||||
3-Year Book Growth Rate | -38.6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 19.37 | |||||
9-Day RSI | 24.37 | |||||
14-Day RSI | 28.17 | |||||
3-1 Month Momentum % | -1.74 | |||||
6-1 Month Momentum % | -2.2 | |||||
12-1 Month Momentum % | -2.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.51 | |||||
Quick Ratio | 0.51 | |||||
Cash Ratio | 0.08 | |||||
Days Sales Outstanding | 169.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | -15.04 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -436.13 | |||||
Net Margin % | -448.22 | |||||
EBITDA Margin % | -435.86 | |||||
FCF Margin % | -418.24 | |||||
OCF Margin % | -418.24 | |||||
ROE % | -321.03 | |||||
ROA % | -133.36 | |||||
ROIC % | -173.03 | |||||
3-Year ROIIC % | 48.4 | |||||
ROC (Joel Greenblatt) % | -2640.46 | |||||
ROCE % | -179.84 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 10.09 | |||||
PB Ratio | 6.01 | |||||
Price-to-Tangible-Book | 19.44 | |||||
EV-to-EBIT | -2.58 | |||||
EV-to-EBITDA | -2.58 | |||||
EV-to-Revenue | 11.25 | |||||
EV-to-Forward-Revenue | 0.34 | |||||
EV-to-FCF | -2.74 | |||||
Earnings Yield (Greenblatt) % | -38.8 | |||||
FCF Yield % | -41.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OncoZenge AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 5.84 | ||
| EPS (TTM) (kr) | -1.67 | ||
| Beta | 0.636 | ||
| 3-Year Sharpe Ratio | 0.68 | ||
| 3-Year Sortino Ratio | 1.19 | ||
| Volatility % | 55.2 | ||
| 14-Day RSI | 28.17 | ||
| 14-Day ATR (kr) | 0.503469 | ||
| 20-Day SMA (kr) | 4.586947 | ||
| 12-1 Month Momentum % | -2.51 | ||
| 52-Week Range (kr) | 3.262331 - 8.577177 | ||
| Shares Outstanding (Mil) | 16.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OncoZenge AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OncoZenge AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-18 | In 163 days | ||
| Third quarter earnings results for 2026 | 2026-11-11 | In 64 days | ||
| Second quarter earnings results for 2026 | 2026-08-27 | 5.01 (+25.79%) | ||
| General meeting for 2025 | 2026-05-27 14:00 | 6.26 (-1.06%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 5.67 (+5.10%) | ||
| Annual report for 2025 | 2026-04-30 | 5.32 (+7.05%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 4.81 (+1.23%) | ||
| Third quarter earnings results for 2025 | 2025-11-20 | 4.73 (-0.70%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 6.17 (+5.87%) | ||
| General meeting for 2024 | 2025-05-28 14:00 | 4.41 (+7.52%) |
Show
Entries
OncoZenge AB Frequently Asked Questions
What is OncoZenge AB(OSTO:ONCOZ)'s stock price today?
The current price of OSTO:ONCOZ is kr3.50. The 52 week high of OSTO:ONCOZ is kr8.58 and 52 week low is kr3.26.
When is next earnings date of OncoZenge AB(OSTO:ONCOZ)?
The next earnings date of OncoZenge AB(OSTO:ONCOZ) is 2026-11-11.
Does OncoZenge AB(OSTO:ONCOZ) pay dividends? If so, how much?
OncoZenge AB(OSTO:ONCOZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on OncoZenge AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers